vs
Side-by-side financial comparison of PRICESMART INC (PSMT) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× PRICESMART INC). Zoetis runs the higher net margin — 25.3% vs 2.9%, a 22.4% gap on every dollar of revenue. On growth, PRICESMART INC posted the faster year-over-year revenue change (9.9% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $32.6M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 3.5%).
PRICESMART INCPSMTEarnings & Financial Report
PriceSmart, Inc. is a United States based operator of membership warehouse clubs in Central America, the Caribbean, and South America. PriceSmart was founded by Sol and Robert Price, founders of Price Club; Robert Price is chairman of the board.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PSMT vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $40.2M | $603.0M |
| Gross Margin | 17.7% | 70.2% |
| Operating Margin | 4.6% | 31.9% |
| Net Margin | 2.9% | 25.3% |
| Revenue YoY | 9.9% | 3.0% |
| Net Profit YoY | 7.3% | 3.8% |
| EPS (diluted) | $1.29 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.2B | $2.4B | ||
| Q2 24 | $1.2B | $2.4B | ||
| Q1 24 | $1.3B | $2.2B |
| Q4 25 | $40.2M | $603.0M | ||
| Q3 25 | $31.5M | $721.0M | ||
| Q2 25 | $35.2M | $718.0M | ||
| Q1 25 | $43.8M | $631.0M | ||
| Q4 24 | $37.4M | $581.0M | ||
| Q3 24 | $29.1M | $682.0M | ||
| Q2 24 | $32.5M | $624.0M | ||
| Q1 24 | $39.3M | $599.0M |
| Q4 25 | 17.7% | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | 17.1% | 72.0% | ||
| Q4 24 | 17.4% | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 4.6% | 31.9% | ||
| Q3 25 | 4.0% | 37.0% | ||
| Q2 25 | 4.3% | 36.7% | ||
| Q1 25 | 4.8% | 36.5% | ||
| Q4 24 | 4.6% | 31.6% | ||
| Q3 24 | 4.0% | 36.6% | ||
| Q2 24 | 4.1% | 33.0% | ||
| Q1 24 | 4.9% | 34.1% |
| Q4 25 | 2.9% | 25.3% | ||
| Q3 25 | 2.4% | 30.0% | ||
| Q2 25 | 2.7% | 29.2% | ||
| Q1 25 | 3.2% | 28.4% | ||
| Q4 24 | 3.0% | 25.1% | ||
| Q3 24 | 2.4% | 28.6% | ||
| Q2 24 | 2.6% | 26.4% | ||
| Q1 24 | 3.0% | 27.4% |
| Q4 25 | $1.29 | $1.37 | ||
| Q3 25 | $1.02 | $1.63 | ||
| Q2 25 | $1.14 | $1.61 | ||
| Q1 25 | $1.45 | $1.41 | ||
| Q4 24 | $1.21 | $1.29 | ||
| Q3 24 | $0.94 | $1.50 | ||
| Q2 24 | $1.08 | $1.37 | ||
| Q1 24 | $1.31 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $320.6M | — |
| Total DebtLower is stronger | $180.3M | — |
| Stockholders' EquityBook value | $1.3B | $3.3B |
| Total Assets | $2.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.14× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $320.6M | — | ||
| Q3 25 | $314.2M | $2.1B | ||
| Q2 25 | $262.4M | $1.4B | ||
| Q1 25 | $247.3M | $1.7B | ||
| Q4 24 | $222.2M | $2.0B | ||
| Q3 24 | $225.5M | $1.7B | ||
| Q2 24 | $228.2M | $1.6B | ||
| Q1 24 | $264.2M | $2.0B |
| Q4 25 | $180.3M | — | ||
| Q3 25 | $186.6M | — | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $107.1M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | $135.1M | — | ||
| Q1 24 | $140.0M | — |
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.2B | $5.4B | ||
| Q2 25 | $1.2B | $5.0B | ||
| Q1 25 | $1.2B | $4.7B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $1.1B | $5.2B | ||
| Q2 24 | $1.1B | $5.0B | ||
| Q1 24 | $1.1B | $5.1B |
| Q4 25 | $2.4B | $15.5B | ||
| Q3 25 | $2.3B | $15.2B | ||
| Q2 25 | $2.1B | $14.5B | ||
| Q1 25 | $2.1B | $14.1B | ||
| Q4 24 | $2.1B | $14.2B | ||
| Q3 24 | $2.0B | $14.4B | ||
| Q2 24 | $2.0B | $14.2B | ||
| Q1 24 | $2.0B | $14.3B |
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.12× | — | ||
| Q1 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $71.2M | $893.0M |
| Free Cash FlowOCF − Capex | $32.6M | $732.0M |
| FCF MarginFCF / Revenue | 2.4% | 30.7% |
| Capex IntensityCapex / Revenue | 2.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.77× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $125.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $71.2M | $893.0M | ||
| Q3 25 | $82.1M | $938.0M | ||
| Q2 25 | $52.8M | $486.0M | ||
| Q1 25 | $87.9M | $587.0M | ||
| Q4 24 | $38.5M | $905.0M | ||
| Q3 24 | $41.8M | $951.0M | ||
| Q2 24 | $38.1M | $502.0M | ||
| Q1 24 | $86.6M | $595.0M |
| Q4 25 | $32.6M | $732.0M | ||
| Q3 25 | $25.6M | $805.0M | ||
| Q2 25 | $14.0M | $308.0M | ||
| Q1 25 | $53.2M | $438.0M | ||
| Q4 24 | $10.3M | $689.0M | ||
| Q3 24 | $15.2M | $784.0M | ||
| Q2 24 | $-308.0K | $370.0M | ||
| Q1 24 | $16.4M | $455.0M |
| Q4 25 | 2.4% | 30.7% | ||
| Q3 25 | 1.9% | 33.5% | ||
| Q2 25 | 1.1% | 12.5% | ||
| Q1 25 | 3.9% | 19.7% | ||
| Q4 24 | 0.8% | 29.7% | ||
| Q3 24 | 1.2% | 32.8% | ||
| Q2 24 | -0.0% | 15.7% | ||
| Q1 24 | 1.3% | 20.8% |
| Q4 25 | 2.8% | 6.7% | ||
| Q3 25 | 4.2% | 5.5% | ||
| Q2 25 | 2.9% | 7.2% | ||
| Q1 25 | 2.5% | 6.7% | ||
| Q4 24 | 2.2% | 9.3% | ||
| Q3 24 | 2.2% | 7.0% | ||
| Q2 24 | 3.1% | 5.6% | ||
| Q1 24 | 5.4% | 6.4% |
| Q4 25 | 1.77× | 1.48× | ||
| Q3 25 | 2.60× | 1.30× | ||
| Q2 25 | 1.50× | 0.68× | ||
| Q1 25 | 2.01× | 0.93× | ||
| Q4 24 | 1.03× | 1.56× | ||
| Q3 24 | 1.44× | 1.39× | ||
| Q2 24 | 1.17× | 0.80× | ||
| Q1 24 | 2.20× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PSMT
| Fresh Foods | $454.9M | 33% |
| Caribbean Operations Segment | $396.5M | 29% |
| Colombia Operations Segment | $204.1M | 15% |
| Hardlines | $162.6M | 12% |
| Softlines | $99.8M | 7% |
| ship Income Member | $24.5M | 2% |
| Health Services | $14.5M | 1% |
| Other Revenue And Income | $4.2M | 0% |
| United States Operations Segment | $510.0K | 0% |
| Export Sales | $359.0K | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
